Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine

Scendoni, Roberto; Petrelli, Cristina; Scaloni, Giorgia; Logullo, Francesco

doi:10.1080/21645515.2021.1954826

Cited by 34 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neurological adverse events such as cerebral sinus venous thrombosis, intracranial hemorrhage that are associated with thrombocytopenia (termed as thrombocytopenia with thrombosis syndrome or vaccine-induced thrombocytopenia with thrombosis), and Guillain-Barré syndrome are also increasingly reported after receiving COVID-19 vaccines, particularly ChAdOx1 nCoV-19 (Oxford/AstraZeneca) [11] and Ad26.COV 2.S [12]. Few cases of GBS after receiving BNT162b2 are reported [5,8,9]. Guillain-Barré syndrome is an acute immune-mediated heterogenous neurological disease affecting peripheral nerves and nerve roots, which is typically preceded by bacterial or viral infections.…”

Section: Discussionmentioning

confidence: 99%

“…A smaller proportion of cases are also associated with surgery, trauma, and vaccinations [1][2][3]. Recently, cases of GBS have been reported after vaccination against coronavirus disease 2019 (COVID-19) [4][5][6][7][8][9][10]. We are reporting the first known case of Guillain-Barré syndrome with sub-acute onset that occurred after receiving the first dose of an mRNA-1273 vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report

Nagalli

Kikkeri

2022

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Ever since the start of the pandemic, SARS-CoV-2 has taken the lives of millions of people around the globe. Several COVID-19 vaccines have been developed with rapidity to prevent acquiring COVID-19 infection, hospitalizations, and deaths. The routine side effects of these vaccines are commonly known and non-severe. Few serious side effects such as thrombosis with thrombocytopenia syndrome (TTS) and Guillain-Barré syndrome (GBS) are increasingly reported particularly after inoculation with ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and Ad26.COV 2.S (Johnson & Johnson’s Janssen). Rare cases of GBS after BNT162b2 (Pfizer-BioNTech), an mRNA vaccine, are also reported. However, the true association of these cases to COVID-19 continues to be unclear and the safety of these vaccines continues to be great in preventing deaths from COVID-19 infection. We report a case of middle-aged female who had a gradual onset of lower extremity weakness with a nadir of symptoms reached 10 and 12 weeks after the onset. This protracted course (sub-acute) is atypical for a “classical” GBS. The presence of an antecedent event, autonomic symptoms such as hypotension, and the need for ventilator support favored the diagnosis of GBS than chronic inflammatory demyelinating polyneuropathy (CIDP). This is the first known case to be reported of sub-acute onset of Guillain-Barré syndrome after receiving the mRNA-1273 vaccine. Supplementary Information The online version contains supplementary material available at 10.1007/s42399-022-01124-1.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report

Nagalli

Kikkeri

2022

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…Neurological AEs that developed after administration of the Pfizer-BioNTech COVID-19 vaccine were tingling, numbness, limb weakness, vertigo, seizure, and loss of consciousness. Bell's palsy and Guillain-Barre syndrome were reported in some cases [3,4]. Brain structural damage has been rarely reported after the Pfizer-BioNTech COVID-19 vaccine.…”

mentioning

confidence: 99%

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine

2021

View full text Add to dashboard Cite

“…Another case of GBS developing after the second dose of the Pfizer vaccine was reported in an 82-year-old Italian female. 17 …”

Section: Discussionmentioning

confidence: 99%

Guillain-Barre Syndrome After Two COVID-19 Vaccinations: Two Case Reports With Follow-up Electrodiagnostic Study

Kim

Park

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

Guillain-Barre syndrome (GBS) is an immune-mediated acute polyradiculoneuropathy and commonly occurs after a preceding infection or immunization sequalae. Following the severe acute respiratory syndrome-coronavirus-2 virus pandemic with co-introduction of massive vaccinations, several GBS cases associated with coronavirus disease 2019 (COVID-19) infection per se or after vaccination for COVID-19 were reported internationally. Herein, we report two cases of Korean GBS presenting with tetraplegia after two different COVID-19 vaccinations (42-year old man by AstraZeneca and 48-year woman by Pfizer vaccines) within four weeks after vaccination. The patients were diagnosed with clinical examination, serial electromyography, and compatible laboratory results and improved after comprehensive rehabilitative treatment and intravenous immunoglobulin therapy. Furthermore, we performed an electrodiagnostic follow-up study of each case to examine their unique characteristics.

show abstract

Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine

Cited by 34 publications

References 9 publications

Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report

Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report

A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine

Guillain-Barre Syndrome After Two COVID-19 Vaccinations: Two Case Reports With Follow-up Electrodiagnostic Study

Contact Info

Product

Resources

About